Hey there, you sneaky little DNA fragment. Yes, you - the circulating tumor DNA floating around in someone's bloodstream right now, thinking you're invisible. You've been slipping past detection for years, hiding in a sea of normal cell-free DNA like a spy in a crowded marketplace. But scientists...
Tomorrow morning, a woman with metastatic ER-positive breast cancer will learn her tumors have stopped responding to chemotherapy. Her oncologist will flip through the limited options remaining, searching for something - anything - that might buy more time. What if the answer has been sitting in...
Forty percent. That's roughly the local recurrence rate for colorectal cancer patients who receive radiotherapy. You'd think blasting tumors with radiation would be enough to rally the immune system into action, but cancer cells have been running a surprisingly sophisticated sabotage operation...
Pulmonary sarcomatoid carcinoma and a Marvel villain have more in common than you'd think. Both are rare, both are terrifyingly aggressive, and both seem designed to make heroes' lives miserable. But unlike the Avengers, oncologists fighting PSC have been working without a decent playbook—until now.
Like the mystery of why socks vanish in the dryer or how Amelia Earhart disappeared over the Pacific, there's been a baffling puzzle haunting American healthcare: we have a screening test that can catch lung cancer early and cut deaths by 20%, yet barely anyone actually gets it. We're talking about...
Your immune system has been doing reps for years, but it took a little pharmaceutical personal training to really see results. Think of the HPV vaccine as the world's most effective workout plan for your immune cells - and the gains are finally showing up in the data.
Glioblastoma doesn't just grow. It builds an entire ecosystem around itself - what scientists call the tumor microenvironment. Think of it as the tumor's personal support staff: blood vessels delivering supplies, immune cells that should be fighting but have been convinced to stand down, and a...
Picture the most audacious heist in cellular history. The target? Branched-chain amino acids—the premium fuel that keeps your immune system's elite strike force running. The thieves? Glioblastoma cells, pulling off a metabolic caper so sophisticated it would make Danny Ocean jealous. And until now,...
Hey there, Medicare budget line items. Yeah, you - the ones labeled "cancer care spending." We need to talk.
For years, there was this awkward silence in photodynamic therapy research - the kind of silence that happens when everyone's pretending not to notice the elephant in the room. The elephant? Tumors are often hypoxic, meaning they're low on oxygen. And the main weapon we had against them - a...
What if you could waltz into a tumor's personal security detail and just... hand them all pink slips? Sounds ridiculous, right? But that's essentially what researchers just pulled off in a clinical trial for metastatic triple-negative breast cancer, and the results are making immunologists do a...
Growing up, I was obsessed with X-Men. Not for Wolverine's claws or Storm's weather powers, but for the concept of "second-generation mutants" - the ones who learned from their predecessors' mistakes and came back stronger, smarter, more refined. Little did I know that decades later, I'd be writing...
In Memoriam: Traditional Protein Inhibition (1970s - 2026)
The problem with lumping all Asian Americans into one statistical bucket is that you end up with a survival rate smoothie - technically accurate on average, but completely useless for understanding what's actually happening to real people.
Ladies and gentlemen of the jury, the evidence has been presented. The defendant: elranatamab, a new bispecific antibody treatment for multiple myeloma. The charge: being oversold based on clinical trial data that doesn't quite match the messy reality of actual patients. The verdict? It's...
Let me be honest with you: I've read enough "revolutionary breakthrough" papers to last several lifetimes. So when a study comes along suggesting we might be able to dial back toxic chemotherapy in kids with brain tumors without hurting their survival, my first instinct is to squint suspiciously at...
A researcher stares at a spreadsheet, watching numbers tick upward. Not stock prices, not social media engagement - these are screening rates for lung cancer, creeping from 17% to nearly 25%. Somewhere, a patient just clicked a link in a text message and scheduled a CT scan that might catch a tumor...
If MIRAI had a LinkedIn, its headline would read: "AI Risk Predictor | Better at spotting trouble than your doctor's questionnaire | Occasionally dramatic about low-risk patients."
If cancer treatment were a final exam, you'd think passing it - surviving five or more years - would earn you straight A's and permanent summer vacation. But for people who beat diffuse large B-cell lymphoma (DLBCL), it turns out the body keeps handing out surprise quizzes. And the subject?...
Watch closely. In one hand, we have imatinib—the drug that transformed chronic myeloid leukemia from a death sentence into a manageable condition back in 2001. Revolutionary stuff. In the other hand, we have the newer second-generation TKIs that promised even better results. And now, for the...